OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia

July 14th 2020

Steven P. Treon, MD, PhD, discusses the role of BTK inhibitors in Waldenström macroglobulinemia.

Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies

July 14th 2020

Kami J. Maddocks, MD, discusses the role of zanubrutinib in B-cell malignancies.

Dr. Raje on the Design of the ENDURANCE Trial in Newly Diagnosed Multiple Myeloma

July 14th 2020

Noopur S. Raje, MD, discusses the design of the randomized phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Dr. Bach on the Results of a Systematic Review of ctDNA in CRC

July 14th 2020

Sander Bach, MD, PhD, discusses the results of a systematic review of circulating tumor DNA in colorectal cancer.

Dr. Leslie on the Current Frontline Treatment Landscape in MCL

July 14th 2020

Lori A. Leslie, MD, discusses the current frontline treatment landscape in mantle cell lymphoma.

Dr. Martin on the Frontline Treatment Landscape of MCL

July 13th 2020

Peter Martin, MD, discusses the frontline treatment landscape of mantle cell lymphoma.

Dr. Verstovsek on the Rationale Behind Treating Myelofibrosis With CPI-0610/Ruxolitinib

July 13th 2020

Srdan Verstovsek, MD, PhD, discusses research efforts being made with CPI-0610 in the treatment of patients with myelofibrosis.

Dr. Costa on the Design of a First-in-Human Study With CC-93269 in R/R Myeloma

July 13th 2020

Luciano J. Costa, MD, PhD, discusses the design of a phase 1 first-in-human study with CC-93269 in relapsed/refractory multiple myeloma.

Dr. Stenzl on the Safety Profile of Enzalutamide/ADT in mHSPC

July 13th 2020

Arnulf Stenzl, MD, discusses the safety profile of enzalutamide in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.

Dr. Ahn on Left- Versus Right-Sided Tumors in CRC

July 13th 2020

Daniel H. Ahn, DO, discusses left- versus right-sided tumors in colorectal cancer.

Dr. Tzachanis on the Likelihood of Cure With CAR T-Cell Therapy in Lymphoma

July 13th 2020

Dimitrios Tzachanis, MD, PhD, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.

Dr. Pennell on Challenges With NGS in Lung Cancer

July 10th 2020

Nathan Pennell, MD, PhD, discusses challenges with next-generation sequencing in lung cancer.

Dr. Sartor on the Significance of the REASSURE Trial in mCRPC

July 10th 2020

Oliver Sartor, MD, discusses the significance of the REASSURE trial in patients with metastatic castration-resistant prostate cancer.

Dr. Daver on Updated Findings With Magrolimab/Azacitidine in MDS

July 10th 2020

Naval G. Daver, MD, discusses updated findings on the combination of the investigational CD47-directed antibody magrolimab and azacitidine in myelodysplastic syndrome.

Dr. Rudin on the Design of the KEYNOTE-604 Trial in ES-SCLC

July 9th 2020

Charles M. Rudin, MD, PhD, discusses the design of the phase 3 KEYNOTE-604 trial in extensive-stage small cell lung cancer.

Dr. Halmos on the Importance of Identifying Biomarkers in Advanced NSCLC

July 9th 2020

Balazs Halmos, MD, MS, discusses the importance of identifying biomarkers in advanced non–small cell lung cancer.

Dr. Eggermont on Responses to Adjuvant Pembrolizumab in Stage III Melanoma Subtypes

July 9th 2020

Alexander M. M. Eggermont, MD, PhD, discusses responses to adjuvant pembrolizumab in patients with different subtypes of stage III melanoma.

Dr. Morris on the Design of the Phase 3 CONDOR Trials in Recurrent Prostate Cancer

July 9th 2020

Michael J. Morris, MD, discusses the design of the phase 3 CONDOR trial in men with biochemically recurrent prostate cancer.

Dr. Lin on Developing Systemic Therapies for Patients with Brain Metastases in HER2+ Breast Cancer

July 9th 2020

Nancy U. Lin, MD, discusses the development of systemic therapies for the treatment of patients with metastatic HER2-positive breast cancer and brain metastases.

Dr. Ghia on Efficacy and Safety of Acalabrutinib in Relapsed/Refractory CLL

July 9th 2020

Paolo Ghia, MD, PhD, discusses the efficacy and safety of acalabrutinib in the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.